38877-93-9

Usage

Uses

Used in Pharmaceutical Industry:
(E)-6-(1,3-Dihydro-4,6-diMethoxy-7-Methyl-3-oxo-5-isobenzofuranyl)-4-Methyl-4-hexenoic Acid is used as an immunosuppressant drug for preventing organ rejection in transplantation procedures. It functions as a selective inhibitor of lymphocyte proliferation by blocking inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of purine nucleotides. This inhibition helps to suppress the immune response, reducing the risk of transplant rejection and improving the success rate of organ transplants.
Additionally, due to its structural similarity to Mycophenolic Acid, it may also have potential applications in the treatment of autoimmune diseases and inflammatory conditions, where immunosuppression is required to manage the symptoms and progression of the disease. Further research and clinical trials would be necessary to explore these potential applications and establish the safety and efficacy of (E)-6-(1,3-Dihydro-4,6-diMethoxy-7-Methyl-3-oxo-5-isobenzofuranyl)-4-Methyl-4-hexenoic Acid in these contexts.

Upstream product

• 207398-35-4 3-((E)-3,7-Dimethyl-octa-2,6-dienyl)-6-(2,2-dimethyl-propionyloxymethyl)-5-formyl-2,4-dihydroxy-benzoic acid methyl ester 
• 545392-50-5 6-[5-(3,3-dimethyl-oxiranyl)-3-methyl-pent-2-enyl]-5,7-dimethoxy-4-methyl-3H-isobenzofuran-1-one 
• 207402-10-6 3-((E)-3,7-Dimethyl-octa-2,6-dienyl)-6-(2,2-dimethyl-propionyloxymethyl)-5-hydroxymethyl-2,4-dimethoxy-benzoic acid methyl ester 
• 207402-09-3 3-((E)-3,7-Dimethyl-octa-2,6-dienyl)-6-(2,2-dimethyl-propionyloxymethyl)-5-formyl-2,4-dimethoxy-benzoic acid methyl ester 
• 207398-36-5 3-((E)-3,7-Dimethyl-octa-2,6-dienyl)-6-(2,2-dimethyl-propionyloxymethyl)-2,4-dimethoxy-5-methyl-benzoic acid methyl ester 
• 207398-37-6 6-((E)-3,7-Dimethyl-octa-2,6-dienyl)-5,7-dimethoxy-4-methyl-3H-isobenzofuran-1-one 
• 60435-90-7 5,7-dimethoxy-6-(5-methoxycarbonyl-3-methyl-2-pentenyl)-4-methylphthalide 
• 545392-47-0 (E)-6-(4,6-Dimethoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enal 

Downstream Products

• 60435-90-7 5,7-dimethoxy-6-(5-methoxycarbonyl-3-methyl-2-pentenyl)-4-methylphthalide 
• 144-62-7 oxalic acid 
• 64-19-7 acetic acid 
• 855891-81-5 5-hydroxyoxalyl-4,6-dimethoxy-benzene-1,2,3-tricarboxylic acid-1,2-anhydride 
• 1001329-49-2 C₃₇H₃₇NO₆ 
• 24280-93-1 mycophenolic acid 
• 31858-66-9 methyl mycophenolate 

Relevant academic research and scientific papers

Mycophenolic acid as a latent agonist of PPARγ

Mycophenolic acid (MPA), known as an inhibitor of inosine monophosphate dehydrogenase (IMPDH), was found to inhibit the differentiation of 3T3-L1 pre-adipocytes into mature adipocytes. Although the effect of MPA was attributed to inhibition of IMPDH, we u

Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment

Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogenase (IMPDH), is used worldwide in transplantation. Recently, numerous studies showed its importance in cancer treatment. Consequently, MPA entered clinical trials in advanced multiple myeloma patients

Total synthesis of mycophenolic acid

A convergent total synthesis of the natural compound mycophenolic acid 1 is described. The synthetic strategy for the construction of the hexasubstituted aromatic nucleus was based on a ring annulation sequence, involving a Michael addition reaction and intramolecular Dieckmann condensation reaction in situ as the key step. Subsequent transformations of the substituents afforded the target mycophenolic acid 1.

A total synthesis of mycophenolic acid

A total convergent synthesis of mycophenolic acid 1 from 2-geranyl- dimethyl-1,3-acetonedicarboxylate 2 and 4-pivaloyloxy-2-butynal using a Michael addition-Dieckmann cyclization as key step is described.